ストックスクリーナーアプリを入手
0.00
100.00%
-5.00
前日終値:
$5.00
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$266.14M
収益：
$44.12M
当期純損益:
$-156.25M
株価収益率:
0.00
EPS:
-3.07
ネットキャッシュフロー:
$-154.61M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$5.30
2 Seventy Bio Inc Stock (TSVT) Company Profile
TSVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
|
ONC
Beigene Ltd Adr
|
236.16 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.65 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.49 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.80 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-06-06 | ダウングレード | Goldman | Neutral → Sell |
| 2024-01-31 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-01-31 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-30 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-10-12 | 開始されました | Citigroup | Buy |
| 2023-09-13 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-07-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-05-02 | 開始されました | Goldman | Buy |
| 2022-02-10 | 開始されました | SVB Leerink | Outperform |
| 2022-01-06 | 開始されました | Cowen | Outperform |
| 2021-11-09 | 開始されました | Canaccord Genuity | Buy |
| 2021-11-08 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-08 | 開始されました | Wedbush | Outperform |
すべてを表示
2 Seventy Bio Inc (TSVT) 最新ニュース
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World
Neuroscientific to Acquire Leading Stem Cell Technology - Investing News Network
American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Intech Investment Management LLC - The AM Reporter
Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive
2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
TSVT Up on Acquisition Agreement With BMY for $286 Million - Yahoo Finance
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
2 Seventy Bio Inc (TSVT) 財務データ
収益
当期純利益
現金流量
EPS
2 Seventy Bio Inc (TSVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baird William D III | President and CEO |
Mar 17 '25 |
Sale |
4.95 |
5,092 |
25,180 |
1,121,034 |
| Eatwell Victoria | Chief Financial Officer |
Mar 17 '25 |
Sale |
4.95 |
2,592 |
12,817 |
444,387 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
11,095,936 |
54,702,964 |
0 |
| Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
5,142,111 |
25,350,607 |
0 |
| Snow Jessica | See Remarks |
Jan 06 '25 |
Sale |
2.79 |
5,114 |
14,289 |
147,365 |
| Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
| Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
| Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
| Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
| Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
0.78%
3.62%
大文字化:
|
ボリューム (24 時間):